OakChart

Editas Medicine Inc

EDITHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

2.38-0.12 (-4.99%)
2026-11-11 22:55 CET
Market cap
384.72 USD m
Revenue, TTM
49.83 USD m
Net income, TTM
-72.22 USD m
Free cash flow, TTM
-110.46 USD m
EPS diluted, TTM
-0.62
P/E
-
Compare

Price

EDIT against its 20, 50 and 200-day averages
2050200beat
2.503.003.504.008.5M17.0MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26EDITclose 2.3820-day 2.5750-day 2.67200-day 2.702.3852w high

39.6% under the 52-week high of 3.94 on 27 May 2026. 52-week low 1.66 on 5 Feb 2026. Last 15 sessions, 30.7% high to low

Volume 0.73× normal · the line is the 50-bar volume average

Profile

EDIT
52-week range, 32% of the way up
1.663.94

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu on September 3, 2013 and is headquartered in Cambridge, MA.

IndexRUT
Employees87
IPOFeb 03, 2016
Beta2.08
ATR, 14d0.23
Rel volume0.73
Short float27.95%
Insider own9.80%
Inst own69.84%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap367.33M
Enterprise Value247.89M
Income-72.22M
Sales49.83M
Book/sh0.55
Cash/sh1.23
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees87
IPOFeb 03, 2016

Ratios

P/E-
Forward P/E-
PEG-
P/S7.37
P/B4.33
P/C1.93
P/FCF-
EV/EBITDA-
EV/Sales4.97
Quick Ratio2.82
Current Ratio2.82
Debt/Eq0.84
LT Debt/Eq0.67
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.62
EPS next Y-0.69
EPS next Q-0.18
EPS this Y58.63%
EPS next Y6.75%
EPS next 5Y28.02%
EPS past 3/5Y17.49% 1.84%
Sales past 3/5Y27.15% -14.89%
EPS Y/Y TTM74.00%
Sales Y/Y TTM7.43%
EPS Q/Q45.37%
Sales Q/Q37.41%
EarningsNov 09 BMO
EPS/Sales Surpr.19.05% 132.43%

Ownership

Insider Own9.80%
Insider Trans-0.19%
Inst Own69.84%
Inst Trans19.43%
ROA-34.30%
ROE-147.44%
ROIC-51.12%
Gross Margin95.81%
Oper. Margin-166.97%
Profit Margin-144.95%
SMA20-7.37%
SMA50-10.85%
SMA200-11.83%
Trades-

Technical

Shs Outstand153.66M
Shs Float138.53M
Short Float27.95%
Short Ratio14.33
Short Interest38.72M
52W High3.94 -39.59%
52W Low1.66 43.37%
Volatility11.02% 9.06%
ATR (14)0.23
RSI (14)42.99
Beta2.08
Rel Volume0.73
Avg Volume2.70M
Volume1,968,821

Performance

Perf Week-12.50%
Perf Month-2.66%
Perf Quarter-15.30%
Perf Half Y-17.93%
Perf YTD16.10%
Perf Year-10.53%
Perf 3Y-68.97%
Perf 5Y-93.77%
Perf 10Y-85.44%
Recom2.00
Target Price5.11
Prev Close2.51
Price2.38
Change %-4.99%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 08, 2026UpgradeWWells FargoEqual Weight → Overweight$6+152.1%
Sep 23, 2026UpgradeGGuggenheimNeutral → Buy$5+110.1%
Aug 18, 2026InitiatedLLadenburg ThalmannBuy$6+152.1%
Apr 28, 2025InitiatedHH.C. WainwrightBuy$3+26.1%
Dec 16, 2024DowngradeJJP MorganNeutral → Underweight
Dec 13, 2024DowngradeTTruistBuy → Hold
Dec 13, 2024DowngradeSStifelBuy → Hold$11 → $3+26.1%
Dec 13, 2024DowngradeCChardan Capital MarketsBuy → Neutral
Dec 11, 2024DowngradeWWells FargoOverweight → Equal Weight$7 → $4+68.1%
Nov 25, 2024DowngradeBBofA SecuritiesBuy → Underperform$13 → $1-58.0%

Peers

Mkt cap
TickerCompanyMkt cap
NTLAIntellia Therapeutics Inc1.60B
BEAMBeam Therapeutics Inc2.67B
PRMEPrime Medicine Inc779.92M
CRSPCRISPR Therapeutics AG4.44B
DTILPrecision Biosciences Inc255.61M
WVEWave Life Sciences Inc674.52M
KRROKorro Bio Inc197.78M
SANASana Biotechnology Inc686.16M
RGNXRegenxbio Inc560.06M
NAMSNewAmsterdam Pharma Company NV2.48B

Insider trading

latest 14 of 20
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Burkly LindaEVP, CHIEF SCIENTIFIC OFFICERSep 03 '26Sale3.047092,15361,660Sep 04 04:27 PM
Parison AmySVP, Chief Financial OfficerSep 03 '26Sale3.044531,37613,839Sep 04 04:25 PM
O'Neill Gilmore NeilCEOSep 03 '26Sale3.045,12415,563243,189Sep 04 04:22 PM
O'Neill Gilmore NeilOfficerSep 03 '26Proposed Sale3.285,10016,728Aug 31 04:11 PM
Burkly LindaOfficerSep 03 '26Proposed Sale3.287002,296Aug 31 04:09 PM
Parison AmySVP, Chief Financial OfficerAug 03 '26Sale2.586781,74914,292Aug 05 04:07 PM
Burkly LindaEVP, CHIEF SCIENTIFIC OFFICERJul 28 '26Sale2.674,92813,15862,369Jul 29 04:51 PM
Burkly LindaOfficerJul 27 '26Proposed Sale2.885,50015,840Jul 21 04:37 PM
Parison AmySVP, Chief Financial OfficerJun 03 '26Sale2.704641,25314,970Jun 05 04:33 PM
O'Neill Gilmore NeilCEOJun 03 '26Sale2.7015,38041,543248,313Jun 05 04:33 PM
Burkly LindaEVP, CHIEF SCIENTIFIC OFFICERJun 03 '26Sale2.707311,97567,297Jun 05 04:32 PM
O'Neill Gilmore NeilOfficerJun 03 '26Proposed Sale3.0815,00046,200May 29 04:40 PM
O'Neill Gilmore NeilCEOMar 03 '26Sale2.025,39410,894263,693Mar 04 04:56 PM
Parison AmySVP, Chief Financial OfficerMar 03 '26Sale2.0247495715,434Mar 04 04:49 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IBBiShares Biotechnology ETFAUM: 11.36B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
IWCiShares Micro-Cap ETFAUM: 1.22B
VHTVanguard Health Care ETFAUM: 21.51B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-09-0.150-0.185-0.15010.374.4612
2026Q22026-08-05-0.150-0.271-0.15311.892.8510
2026Q12026-05-05-0.260-0.263-0.2552.836.3710
2025Q42026-03-09-0.060-0.233-0.05824.748.3513
2025Q32025-11-10-0.280-0.296-0.2797.544.9413
2025Q22025-08-12-0.630-0.391-0.6313.582.3112
2025Q12025-05-12-0.920-0.564-0.9164.660.6412
2024Q42025-03-05-0.550-0.377-0.55230.6029.7615
2024Q32024-11-04-0.750-0.747-0.7530.063.9318
2024Q22024-08-07-0.820-0.704-0.8210.514.7817
2024Q12024-05-08-0.760-0.626-0.7561.1411.1415
2023Q42024-02-28-0.230-0.594-0.23160.053.7015
2023Q32023-11-03-0.550-0.575-0.5515.343.7017
2023Q22023-08-02-0.560-0.767-0.5652.894.1717
2023Q12023-05-05-0.710-0.784-0.7119.853.2917
2022Q42023-02-22-0.880-0.789-0.8836.543.6620

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-2.680-1.828-2.67620.5056.06
2020FY-1.980-1.702-1.97990.7385.15
2021FY-2.850-3.011-2.84725.5417.41
2022FY-3.210-3.048-3.21019.7116.59
2023FY-2.020-2.396-2.01778.1221.99
2024FY-2.880-2.701-2.88032.3134.36
2025FY-1.800-1.978-1.80140.5224.14
2026FY--0.745--29.65
2027FY--0.694--20.66
2028FY--0.671--16.52
2029FY--0.648--18.45
2030FY--0.644--19.60

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-1012216.551.0020.00
2026Q4S2026-11-0912116.431.0020.00
2026Q4S2026-11-0412106.691.0020.00
2026Q4S2026-11-0312106.691.0020.00
2026Q4S2026-10-2112006.521.0020.00
2026Q4S2026-10-2012026.521.0020.00
2026Q4S2026-09-2212226.521.0020.00
2026Q4S2026-08-1711226.661.0020.00
2026Q4S2026-08-0710226.111.0020.00
2026Q4S2026-08-0610206.591.0020.00
2026Q4S2026-07-229006.681.0020.00
2026Q4S2026-07-219016.681.0020.00
2026Q4S2026-07-199116.681.0020.00
2026Q4S2026-06-179136.681.0020.00

Estimate history

EPS, annual-2.98-2.335-2.676-1.979-2.847-3.21-2.017-2.88-1.804-0.6181
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.753-0.552-0.916-0.631-0.279-0.058-0.255-0.153-0.152
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual13.72831.93720.53190.73225.54419.71278.12332.31440.5249.83
Period201720182019202020212022202320242025TTM
Sales, quarterly0.06130.6044.6583.5787.54324.7412.83111.8910.365
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual44.50848.75954.35662.56368.43568.84781.76782.73597.867153.658
Period201720182019202020212022202320242025MRQ
Shares, quarterly82.53982.73583.7187.38893.26497.86797.867153.531153.658
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue49.8340.5232.3178.1219.7125.5490.7320.5331.94
Cost of Goods Sold Incl. D&A2.095.285.816.066.345.05---
Gross Profit47.7435.2426.5072.0613.3820.49---
Selling, General and Administrative Excl. Other130.93134.58265.43241.24239.32213.64221.61158.62142.41
Research and Development84.2784.68193.44171.59168.62137.45154.0494.0790.65
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-83.19-99.34-238.92-169.18-225.95-193.15-134.84-140.92-113.73
Interest Expense-6.170.000.000.000.000.00--
Unusual Expense-7.6060.6712.230.000.001.70-16.26--
Net Income Before Taxes-72.22-160.06-237.09-153.22-220.43-192.50-115.98-133.75-109.95
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-72.22-160.06-237.09-153.22-220.43-192.50-115.98-133.75-109.95
Net Income From Continuing Operations-72.22-160.06-237.09-153.22-220.43-192.50-115.98-133.75-109.95
Net Income-72.22-160.06-237.09-153.22-220.43-192.50-115.98-133.75-109.95
EPS (Recurring)-0.50-1.32-2.78-2.02-3.21-2.83-2.17-2.68-2.33
EPS (Basic, Before Extraordinaries)-0.62-1.80-2.88-2.02-3.21-2.85-1.98-2.68-2.33
EPS (Diluted)-0.62-1.80-2.88-2.02-3.21-2.85-1.98-2.68-2.33
EBITDA-81.11-94.06-233.11-163.12-219.61-188.09-130.88-138.09-110.47
Non-Operating Income (Expense)6.586.1214.0615.965.522.342.607.183.77
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense8.9910.0021.4219.8029.2943.4023.1627.2426.60
Price To Sales Ratio7.924.493.249.8530.9070.2845.2972.0933.55
Gross Margin95.8186.9882.0292.2467.8580.22---
Operating Margin-166.97-245.15-739.37-216.56-1,146.26-756.13-148.61-686.39-356.10
Net Margin-144.95-395.01-733.72-196.13-1,118.26-753.61-127.82-651.43-344.28
Shares Outstanding153.6697.8782.7381.7768.8568.4462.5654.3648.76
Market Capitalization384.72384.72104.84827.35609.931,815.984,370.251,519.081,087.68

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue10.3711.892.8324.747.543.584.6630.60
Cost of Goods Sold Incl. D&A0.390.420.480.810.721.831.921.38
Gross Profit9.9811.472.3523.946.821.742.7429.22
Selling, General and Administrative Excl. Other34.2631.3727.3537.9531.3727.2138.0563.58
Research and Development20.7919.7617.1226.6019.0514.3524.6847.23
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-24.28-19.89-25.00-14.02-24.55-25.46-35.31-34.36
Interest Expense1.081.061.07-2.402.022.220.00
Unusual Expense0.00-1.340.00-6.260.0026.0840.8512.23
Net Income Before Taxes-23.39-18.23-24.98-5.62-25.12-53.23-76.09-45.40
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-23.39-18.23-24.98-5.62-25.12-53.23-76.09-45.40
Net Income From Continuing Operations-23.39-18.23-24.98-5.62-25.12-53.23-76.09-45.40
Net Income-23.39-18.23-24.98-5.62-25.12-53.23-76.09-45.40
EPS (Recurring)-0.15-0.16-0.26-0.10-0.28-0.41-0.57-0.45
EPS (Basic, Before Extraordinaries)-0.15-0.15-0.26-0.06-0.28-0.63-0.92-0.55
EPS (Diluted)-0.15-0.15-0.26-0.06-0.28-0.63-0.92-0.55
EBITDA-23.90-19.48-24.52-13.21-23.83-23.63-33.39-32.98
Non-Operating Income (Expense)1.971.391.092.131.830.332.291.20
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.572.192.102.132.232.662.354.02
Price To Sales Ratio7.928.226.254.926.744.772.693.25
Gross Margin96.2996.5082.9496.7590.4448.7458.8495.49
Operating Margin-234.27-167.31-883.19-56.65-325.44-711.63-758.05-112.28
Net Margin-225.69-153.32-882.44-22.72-332.98-1,487.84-1,633.49-148.33
Shares Outstanding153.66153.5397.8797.8793.2687.3983.7182.73
Market Capitalization384.72497.22241.74200.12312.02184.1796.25104.84

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments146.65269.91323.11344.27499.85402.11457.14368.95329.14
Short Term Receivables15.1816.2710.195.140.276.050.420.030.68
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets2.073.147.537.337.2010.936.295.792.38
Total Current Assets163.90289.31340.83356.75507.31419.09463.84374.78332.20
Net Property, Plant & Equipment19.6647.0545.7159.2243.2939.1539.6540.2339.44
Total Investments and Advances2.703.88107.9096.97123.95113.545.295.381.62
Intangible Assets-------0.000.00
Other Assets0.281.354.711.382.930.830.110.000.00
Total Assets186.53341.59499.15514.32677.48572.60508.88420.39373.26
Short Term Debt Incl. Current Port. of LT Debt11.0314.6512.1611.0810.316.815.800.007.50
Accounts Payable2.605.498.279.515.056.415.845.334.02
Other Current Liabilities32.6157.0842.7839.5231.5244.9948.3230.5725.19
Total Current Liabilities46.2577.2263.2260.1146.8858.2159.9635.9036.71
Long Term Debt65.6820.3824.3732.8616.0719.3223.2832.4233.43
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities47.32109.7162.4760.6760.89101.48163.21115.9195.04
Total Liabilities159.25207.31150.06153.64123.84179.02246.45184.22165.18
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity27.29134.27349.10360.68553.64393.59262.44236.16208.08
Total Shareholders Equity27.29134.27349.10360.68553.64393.59262.44236.16208.08
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity27.29134.27349.10360.68553.64393.59262.44236.16208.08
Total Liabilities & Stockholders Equity186.53341.59499.15514.32677.48572.60508.88420.39373.26
Book Value Per Share0.281.624.275.248.096.294.834.844.68
Tangible Book Value Per Share0.281.624.275.248.096.294.834.844.68
Full-Time Employees87246265226264235208133112
Price to Book Ratio4.550.602.301.473.2811.146.134.707.23
Return on Assets-60.61-56.40-30.24-36.99-30.80-21.45-28.79-27.71-39.95
Return on Equity-198.14-98.10-43.17-48.22-40.65-35.36-53.65-49.50-70.22
Return on Invested Capital-172.17-153.31-41.03-56.01-33.79-28.09-46.81-40.94-49.82
Quick Ratio3.543.755.395.9410.827.207.7410.449.05
Current Ratio3.543.755.395.9410.827.207.7410.449.05

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-72.22-160.06-237.09-153.22-220.43-192.50-115.98-133.75-109.95
Depreciation2.095.285.816.066.345.053.962.833.25
Other Funds (Non Cash)11.3720.7717.5516.5728.5745.066.8924.3234.10
Funds from Operations-58.76-134.01-213.73-130.58-185.53-142.39-105.12-106.60-72.59
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-51.44-31.233.45-1.598.18-21.41-74.7265.9326.89
Cash from Operating Activities-110.21-165.24-210.28-132.18-177.35-163.80-179.84-40.67-45.71
Capital Expenditures-0.26-0.61-8.83-4.72-4.12-7.98-7.16-6.17-4.75
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.270.270.000.000.020.000.010.100.04
Purchase or Sale of Investments-96.68139.01170.970.99118.17-46.49-133.3718.32-48.37
Purchase of Investments-116.680.00-86.22-258.52-315.19-408.89-458.40-342.18-459.37
Sale Or Maturity of Investments20.00139.01257.19259.50433.35362.40325.03360.50411.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-96.67138.67162.15-3.73114.07-54.47-140.5212.25-53.09
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock134.3943.3456.03118.041.28282.11224.12131.8287.80
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock134.3943.3456.03118.041.28282.11224.12131.8287.80
Proceedsfrom Stock Options134.1643.2755.83118.000.00249.46203.73116.3476.79
Issuance or Reduction of Debt, Net0.00-2.870.000.000.000.000.000.00-0.86
Change in Long Term Debt0.00-2.870.000.000.000.000.000.00-0.86
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.00-2.870.000.000.000.000.000.00-0.86
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities134.3940.4756.03118.041.28282.11224.12131.8286.94
Net Change in Cash-72.4813.907.89-17.87-62.0063.84-96.24103.41-11.85
Free Cash Flow-110.46-165.85-219.11-136.90-181.47-171.78-187.00-46.84-50.46
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments190.20211.65123.65146.65165.65178.50
Short Term Receivables7.732.732.5915.188.130.59
Inventories0.000.000.000.000.000.00
Other Current Assets4.053.701.832.073.113.71
Total Current Assets201.97218.07128.07163.90176.89182.80
Net Property, Plant & Equipment14.4616.3218.3019.6621.8723.59
Total Investments and Advances2.672.672.672.702.673.88
Other Assets0.310.310.310.280.320.32
Total Assets219.41237.36149.34186.53201.75210.58
Short Term Debt Incl. Current Port. of LT Debt14.0114.0114.2011.0311.0911.15
Accounts Payable6.824.744.332.603.166.72
Other Current Liabilities50.7649.6821.2532.6147.5248.07
Total Current Liabilities71.5868.4339.7846.2561.7765.94
Long Term Debt56.7557.2457.7765.6867.6366.66
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities6.566.4147.3847.3258.8958.80
Total Liabilities134.89132.08144.93159.25188.30191.39
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity84.52105.284.4127.2913.4519.19
Total Shareholders Equity84.52105.284.4127.2913.4519.19
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity84.52105.284.4127.2913.4519.19
Total Liabilities & Stockholders Equity219.41237.36149.34186.53201.75210.58
Book Value Per Share0.550.690.050.280.140.22
Tangible Book Value Per Share0.550.690.050.280.140.22
Full-Time Employees---87--
Price to Book Ratio4.5571.948.8614.2115.802.95
Return on Assets-34.30-33.02-52.76-60.61-75.51-79.57
Return on Equity-147.44-118.82-326.07-198.14-211.37-188.58
Return on Invested Capital-16.56-11.22-40.17-6.05-30.98-62.01
Quick Ratio2.823.193.223.542.862.77
Current Ratio2.823.193.223.542.862.77

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-23.39-18.23-24.98-5.62-25.12-53.23
Depreciation0.390.420.480.810.721.83
Other Funds (Non Cash)3.353.103.291.644.575.81
Funds from Operations-19.66-14.72-21.21-3.17-19.83-45.59
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.53-14.85-1.85-33.21-11.01-4.62
Cash from Operating Activities-21.19-29.57-23.06-36.39-30.84-50.21
Capital Expenditures0.00-0.11-0.09-0.06-0.430.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.160.120.000.15
Purchase or Sale of Investments-66.99-29.690.000.0040.0142.50
Purchase of Investments-86.99-29.690.000.000.000.00
Sale Or Maturity of Investments20.000.000.000.0040.0142.50
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-66.99-29.800.060.0639.5742.65
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-0.47117.530.0017.3317.177.41
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock-0.47117.530.0017.3317.177.41
Proceedsfrom Stock Options-0.62117.500.0017.2817.157.41
Issuance or Reduction of Debt, Net0.000.000.000.000.00-2.87
Change in Long Term Debt0.000.000.000.000.00-2.87
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.00-2.87
Net Financing Active Other Cash Flow0.000.000.000.000.002.87
Other Financing Activities Uses0.000.000.000.000.002.87
Cash from Financing Activities-0.47117.530.0017.3317.177.41
Net Change in Cash-88.6558.17-23.00-19.0025.90-0.15
Free Cash Flow-21.19-29.67-23.15-36.45-31.28-50.21

Revenue breakdown

Biological Products, (No Diagnostic Substances)2024: 32.31M 2025: 40.52M
United States2024: 32.31M 2025: 40.52M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3027.95%38.7M138.5M2.66M
2026-10-1527.56%38.2M138.5M2.51M
2026-09-3026.79%37.1M138.5M2.53M
2026-09-1521.63%30.0M138.5M2.37M
2026-08-3121.82%30.2M138.5M2.44M
2026-08-1417.82%24.7M138.5M2.56M
2026-07-3116.52%23.5M142.1M2.46M
2026-07-1515.64%22.2M142.0M2.50M
2026-06-3015.83%22.5M142.0M2.32M
2026-06-1512.97%18.4M142.0M2.02M
2026-05-2911.13%15.1M135.3M1.99M
2026-05-159.81%9.6M97.5M1.59M
2026-04-3010.27%10.0M97.4M1.65M
2026-04-1511.21%10.9M97.4M1.73M
2026-03-3112.26%11.9M97.4M1.78M
2026-03-1311.83%11.5M97.4M1.85M
2026-02-2712.24%11.9M97.1M1.75M
2026-02-1312.10%11.7M97.1M1.71M
2026-01-3011.80%11.5M97.1M1.87M
2026-01-1512.18%11.8M97.1M2.00M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.501.502.453.280.00080.000.000.962-0.0220.000
call1.001.001.952.0513.54928.000.000.909-0.0250.001
call1.500.601.401.258.02288.000.000.843-0.0230.001
call2.000.150.750.574.03219.006.000.735-0.0180.001
call2.500.000.100.101.0032,73610.000.438-0.0100.001
call5.000.000.050.053.1931,3760.000.107-0.0120.001
call7.500.000.050.054.3387070.000.087-0.0140.001
put0.500.000.750.0412.7254.000.00-0.038-0.0220.000
put1.000.000.750.057.23111.000.00-0.091-0.0250.001
put1.500.000.250.064.55631.000.00-0.157-0.0230.001
put2.000.000.200.052.6691370.00-0.265-0.0180.001
put2.500.100.350.151.90648614.00-0.562-0.0100.001
put5.002.002.902.305.40013.000.00-0.893-0.0120.001
put7.504.505.505.007.5441.000.00-0.913-0.0140.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-098-KCurrent report2026-11-09SEC
2026-11-064Statement of changes in beneficial ownership of securities2026-11-05SEC
2026-11-064Statement of changes in beneficial ownership of securities2026-11-05SEC
2026-10-27SCHEDULE 13GSEC
2026-10-088-KCurrent report2026-10-08SEC
2026-09-094Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-09-093Initial statement of beneficial ownership of securities2026-09-08SEC
2026-09-09S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-09-08EFFECTEffectiveness filing by commission orderSEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-03SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-03SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-03SEC
2026-08-31144Filing for proposed sale of securities under Rule 144.SEC
2026-08-31144Filing for proposed sale of securities under Rule 144.SEC
2026-08-31S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-08-14SCHEDULE 13GSEC
2026-08-074Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-073Initial statement of beneficial ownership of securities2026-08-06SEC
2026-08-054Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-058-KCurrent report2026-08-03SEC
2026-07-29SCHEDULE 13G/ASEC
2026-07-294Statement of changes in beneficial ownership of securities2026-07-28SEC
2026-07-21144Filing for proposed sale of securities under Rule 144.SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090019.09K3
2026-08001.75K1
2026-070013.16K1
2026-060044.77K3
2026-050000
2026-040000
2026-030013.36K3
2026-020000
2026-010000
2025-120014.59K3
2025-110000

Institutional holders

Manager% owned
TCG Crossover Management, LLC7.24%
BlackRock, Inc.6.90%
Commodore Capital LP5.79%
ADAR1 Capital Management, LLC5.79%
RA CAPITAL MANAGEMENT, L.P.5.79%
VANGUARD CAPITAL MANAGEMENT LLC4.00%
Paradigm Biocapital Advisors LP3.64%
GEODE CAPITAL MANAGEMENT, LLC2.53%
Opaleye Management Inc.2.52%
VANGUARD PORTFOLIO MANAGEMENT LLC2.34%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND3.19%
iShares Russell 2000 ETF1.72%
Nuveen Quant Small Cap Equity Fund1.71%
VANGUARD STRATEGIC EQUITY FUND1.32%
VANGUARD EXTENDED MARKET INDEX FUND0.72%
Fidelity Small Cap Index Fund0.71%
iShares Russell 2000 Growth ETF0.55%
iShares Biotechnology ETF0.45%
VANGUARD RUSSELL 2000 INDEX FUND0.37%
Fidelity Extended Market Index Fund0.34%

OakChart. EDIT. Cached 15 minutes.